Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 17, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

Livio Pagano1, Caterina Giovanna Valentini, Alessandro Pulsoni

  • 1Institute of Hematology, Catholic University, Rome, Italy. lpagano@rm.unicatt.it

Haematologica
|October 16, 2012
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transitory vitreous opacities after CB-PRP intravitreal injections in dry AMD patients.

Therapeutic advances in ophthalmology·2026
Same author

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

HemaSphere·2026
Same author

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same author

Unrelated cord blood transplantation and post-transplant cyclophosphamide.

Haematologica·2026
Same author

Humoral and Cellular Immune Response in Patients with Hematological Disorders After Three Doses of mRNA COVID-19 Vaccine: A Single-Center Observational Study.

Vaccines·2026
Same author

Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification.

Haematologica·2026

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation is aggressive. Acute lymphoid leukemia/lymphoma-type chemotherapy and allogeneic stem cell transplant improved survival in this rare leukemia.

Area of Science:

  • Hematology
  • Oncology
  • Leukemia Research

Background:

  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) with leukemic presentation is a rare and aggressive hematologic malignancy.
  • Understanding its clinical features, prognostic factors, and treatment efficacy is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate clinical characteristics, prognostic indicators, and treatment effectiveness in BPDCN patients with a leukemic onset.
  • To identify optimal therapeutic strategies for this challenging disease.

Main Methods:

  • A retrospective multicenter study involving 28 Italian hematology divisions.
  • Collected data from 43 patients diagnosed with BPDCN between 2005 and 2011.
  • Analyzed induction therapies (AML-type vs. ALL/lymphoma-type regimens) and outcomes, including allogeneic hematopoietic stem cell transplantation (HSCT).

More Related Videos

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Related Experiment Videos

Last Updated: May 17, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Main Results:

  • Complete remission (CR) was achieved in 41% of patients, with a significant advantage for acute lymphoid leukemia/lymphoma-type chemotherapy (P=0.02).
  • Median overall survival (OS) was 8.7 months; patients receiving ALL/lymphoma-type chemotherapy had longer OS (12.3 months) compared to AML-type (7.1 months) (P=0.02).
  • Allogeneic HSCT recipients showed a significant survival advantage (median OS 22.7 months) versus non-transplanted patients (median OS 7.1 months) (P=0.03).

Conclusions:

  • BPDCN with bone marrow involvement is an aggressive, high-risk acute leukemia subtype.
  • Acute lymphoid leukemia/lymphoma-type chemotherapy and allogeneic HSCT appear to be more effective therapeutic strategies.
  • The rarity of BPDCN necessitates experienced-based clinical decision-making in the absence of prospective trials.